Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reinforced Pneumococcal Vaccination in ANCA-Vasculitis
NCT03069703Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Feb 2018
- Primary completion
- Nov 2020
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pneumococcal 13-valent conjugate vaccine in invasive pneumococcal disease (IPD), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Immunogenicity at 6 months. Started Feb 2018; status: completed.
02
Drugs
pneumococcal 13-valent conjugate vaccine
03
Conditions
invasive pneumococcal disease (IPD)
Beyond the preview
Go deeper on NCT03069703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03069703.